Brief communicationLow frequency of hypersensitivity reactions to Abacavir (cas 136470-78-5) in HIV infected patients in a referral center in Bahia, Brazil
-
Add time:09/02/2019 Source:sciencedirect.com
Abacavir (cas 136470-78-5) can cause a multi-systemic hypersensitivity reaction (HSR) in 5–8% of the patients, which is related to HLA-B*57-01 allele. In Brazil, the HLA-B*57-01 screening test became available only in March 2018, several years after abacavir was in use. In this retrospective study we reviewed medical charts of all patients receiving an abacavir-containing regimen to evaluate the frequency of HSR in patients followed at a referral center in Salvador, Brazil. A total of 192 patients who received abacavir were identified, most male (67.1%), black or racially mixed (77.8%), and having diagnosis of a previous AIDS defining conditions (83.7%). Only one patient developed HSR (incidence: 0.52%). The main reasons for abacavir-containing antiretroviral therapy discontinuation were virological failure (28%), adverse effects to other components of the regimen (25%), and simplification of therapy (16%). The low incidence of HSR to abacavir does not support the use of HLA-B*57-01 screening test, in Salvador, Brazil.
We also recommend Trading Suppliers and Manufacturers of Abacavir (cas 136470-78-5). Pls Click Website Link as below: cas 136470-78-5 suppliers
Prev:Abacavir modulates peroxynitrite-mediated oxidation of ferrous nitrosylated human serum heme–albumin
Next:High-efficiency electrochemical degradation of antiviral drug Abacavir (cas 136470-78-5) using a penetration flux porous Ti/SnO2–Sb anode) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Monitoring Abacavir (cas 136470-78-5) bioactivation in humans: Screening for an aldehyde metabolite09/10/2019
- Effect of drug efflux transporters on placental transport of antiretroviral agent Abacavir (cas 136470-78-5)09/09/2019
- Abacavir (cas 136470-78-5) and cardiovascular disease: A critical look at the data09/08/2019
- Abacavir (cas 136470-78-5)☆09/07/2019
- Original articleSwitching from Abacavir (cas 136470-78-5)/lamivudine plus nevirapine to Abacavir (cas 136470-78-5)/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study)Abacavir (cas 136470-78-5)/lamivudine/dolutégravir après Abacavir (cas 136470-78-5)/lamivudine plus névirapine chez des adultes infectés par le VIH et contrôlés virologiquement (étude SWAD)09/06/2019
- ReviewRisk of cardiovascular disease associated with exposure to Abacavir (cas 136470-78-5) among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies09/05/2019
- Case reportAbacavir (cas 136470-78-5)-induced liver toxicity09/04/2019
- High-efficiency electrochemical degradation of antiviral drug Abacavir (cas 136470-78-5) using a penetration flux porous Ti/SnO2–Sb anode09/03/2019


